Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec

4Q Revenues: $708 million (+12%)

4Q Earnings: $109 million (+95%)

FY Revenues: $2.68 billion (+11%)

FY Earnings: $218 million (+35%)

Comments: Revenues for the quarter and FY2006 included $218 million and $811 million, respectively, from Biogen’s joint business arrangement related to Rituxan. For the quarter, Avonex sales were up 6% to $439 million and for the year were up 11% to $1.7 billion. During 2006 the company launched Rituxan in rheumatoid arthritis and Tysabri in multiple sclerosis. R&D expenses for the quarter were $199.5 million, up 19% and $718.4 for the year, down 4%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters